SH

Sotera Health Company

SHCHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot
MA150+15.13%
$16.53

Price above medium-term moving average.

MA200+13.31%
$16.79

Above long-term trend line.

RSI-14neutral
54.5

Balanced. Not overbought, not oversold.

MACDnegative
-0.0930

Histogram negative, downward momentum.

Financials · Annual
Revenue
$1.16B
+5.7% YoY
Net Income
$77.9M
+75.6% YoY
EBITDA
$439.9M
-0.5% YoY
Free Cash Flow
$154.0M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 2 MACD Negative CrossoverHistogram -0.0866, negative momentum
Sep 1 MACD Negative CrossoverHistogram -0.0444, negative momentum
About Sotera Health Company

Part of the healthcare sector, Sotera Health Company (SHC) is listed under Diagnostics & Research. The $5.43B market capitalization puts SHC squarely in mid-cap range for its industry. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs.

Where SHC stands vs its 150-day and 200-day moving averages

As of the September 2, 2026 close, SHC finished 13.08% above its 150-day moving average ($16.52) and 11.46% above its 200-day moving average ($16.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is SHC overbought or oversold?

At the September 2, 2026 close, SHC's RSI(14) was 46.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$5.43B
P/E (TTM)33.39
Fwd P/E17.70
EPS$0.57
Beta1.77
52W Change+21.4%
ROE27.8%
Analysis

Sotera Health Company carries $2.27B in total debt against $357.0M in cash reserves — debt is roughly 6.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $154.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 27.8%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.00B to $1.16B.

A beta of 1.77 means SHC is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing SHC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms